Study the combined effects of amlodipine and simvastatin on lipid profile in Hypertensive obese patients

A study was conducted to evaluate the combined effect of Amlodipine and Simvastatin on the lipid levels of hypertensive obese patients. Amlodipine belongs to the dihydropyridine subclass of calcium antagonist whereas Simvastatin is a competitive inhibitor of HMG-CoA [3Hydroxy 3Methyl Glutaryl Coenzyme A] reductase. Three group of patients of both gender comprises 40 in each were included. Group A [hypertensive obese patients] was given amlodipine, group B [obese patients] was given simvastatin and group C [hypertensive obese patients] was given combination of amlodipine and simvastatin. Blood pressure was checked and tests for serum Cholesterol, serum Triglycerides and serum Lipoprotiens [HDL, LDL] was carried out by Standard kit methods [Merck]. The patients were evaluated three times i.e. before giving the medicines 0 week, at 6[th] and 12[th] week. The patients were advised to take fat free diet and a morning walk. Mean blood pressure of both male and female patients was significantly reduced. It was observed that combined therapy of Amlodipine and Simvastatin, significantly decreased the level of serum cholesterol, triglycerides and LDL-Cholesterol and significantly increased the level of HDL-Cholesterol in both sexes, but they did not show any significant synergistic effect as compared to the levels of these parameters in group A [amlodipine] as well as in group B [simvastatin]. A significant weight reduction is observed in male patients which may be due to low calorie diet and physical exercise. It is therefore concluded that synergism with Amlodipine and Simvastatin is not significant as the major action of Amlodipine is on blood pressure and the major effects of Simvastatin is on lipid profile and also reduced the body weight, if patients used calorie restricted diet with some morning walk